content: SECURITIES AND EXCHANGE COMMISSION
                                WASHINGTON, DC 20549
  
                                  ----------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                         PURSUANT TO SECTION 13 OR 15(D) OF
                         THE SECURITIES EXCHANGE ACT OF 1934
  
  
           Date of report (Date of earliest event reported) April 2, 1997
  
  
                                     SCIOS INC.
                 (Exact Name of Registrant as Specified in Charter)
  
  
  
           Delaware                       0-11749                95-3701481
  (State of Other Jurisdiction          (Commission             (IRS Employer
          of Incorporation)             File Number)          Identification No.)
  
  
  
               2450 Bayshore Parkway, Mountain View, California 94043
                      (Address of Principal Executive Offices)
  
  
  
          Registrant's telephone number, including area code (415) 966-1550
  
  
  <PAGE>
  
  Item 5.  Other Events
  
           On April 2, 1997, Scios Inc. announced that it suspended development of
  AURICULIN(R)  anaritide  for the  treatment  of oliguric  acute  renal  (kidney)
  failure based upon the results of an interim analysis of data. The press release
  is attached hereto as Exhibit 99.2 and incorporated herein by reference.
  
  
  Exhibits.
  
           99.2     Press Release dated April 2, 1997
  
  
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  registrant has duly caused this amendment to be signed on its behalf of the
  undersigned, thereunto duly authorized.
  
                                     SCIOS INC.
  
                                     /s/ John H. Newman
  Date:  April 2. 1997               By:
                                         John H. Newman
                                         Vice President of Legal Affairs
  
  
  <PAGE>
  
  
                                  INDEX TO EXHIBITS
  
                                     SCIOS INC.
  
                       Report on Form 8-K dated April 2, 1997
  
  
  
  
  Exhibit     Description                           Method of Filing
  -------     -----------                           ----------------
  
  99.2        Press Release dated April 2, 1997     Filed electronically herewith
metadata_documents: [{"type": "8-K", "sequence": "1", "description": "FORM 8-K", "secsgml_size_bytes": 2250}]
metadata_filer: {"company-data": {"conformed-name": "SCIOS INC", "cik": "0000726512", "assigned-sic": "5122", "irs-number": "953701481", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-11749", "film-number": "97573900"}, "business-address": {"street1": "2450 BAYSHORE PKWY", "city": "MOUNTAIN VIEW", "state": "CA", "zip": "94043", "phone": "4159661550"}, "mail-address": {"street1": "2450 BAYSHORE PARKWAY", "city": "MOUNTAIN VIEW", "state": "CA", "zip": "94043"}, "former-company": [{"former-conformed-name": "SCIOS INC", "date-changed": "19920703"}, {"former-conformed-name": "CALIFORNIA BIOTECHNOLOGY INC", "date-changed": "19920302"}]}
text: SECURITIES AND EXCHANGE COMMISSION
                                WASHINGTON, DC 20549
  
                                  ----------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                         PURSUANT TO SECTION 13 OR 15(D) OF
                         THE SECURITIES EXCHANGE ACT OF 1934
  
           Date of report (Date of earliest event reported) April 2, 1997
  
                                     SCIOS INC.
                 (Exact Name of Registrant as Specified in Charter)
  
           Delaware                       0-11749                95-3701481
  (State of Other Jurisdiction          (Commission             (IRS Employer
          of Incorporation)             File Number)          Identification No.)
  
               2450 Bayshore Parkway, Mountain View, California 94043
                      (Address of Principal Executive Offices)
  
          Registrant's telephone number, including area code (415) 966-1550
  Item 5.  Other Events
  
           On April 2, 1997, Scios Inc. announced that it suspended development of
  AURICULIN(R)  anaritide  for the  treatment  of oliguric  acute  renal  (kidney)
  failure based upon the results of an interim analysis of data. The press release
  is attached hereto as Exhibit 99.2 and incorporated herein by reference.
  
  Exhibits.
  
           99.2     Press Release dated April 2, 1997
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  registrant has duly caused this amendment to be signed on its behalf of the
  undersigned, thereunto duly authorized.
  
                                     SCIOS INC.
  
                                     /s/ John H. Newman
  Date:  April 2. 1997               By:
                                         John H. Newman
                                         Vice President of Legal Affairs
  INDEX TO EXHIBITS
  
                                     SCIOS INC.
  
                       Report on Form 8-K dated April 2, 1997
  
  Exhibit     Description                           Method of Filing
  -------     -----------                           ----------------
  
  99.2        Press Release dated April 2, 1997     Filed electronically herewith